GILEAD SCIENCES, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GILEAD SCIENCES, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $0.00.
- GILEAD SCIENCES, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $86.00M, a 4.88% increase year-over-year.
- GILEAD SCIENCES, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $0.00.
- GILEAD SCIENCES, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $61.00M, a 5.17% increase year-over-year.
- GILEAD SCIENCES, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $143.00M, a 2.88% increase from fiscal 2024.
- GILEAD SCIENCES, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $139.00M, a 7.75% increase from fiscal 2023.
- GILEAD SCIENCES, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $129.00M, a 25.24% increase from fiscal 2022.
- GILEAD SCIENCES, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $103.00M, a 7.21% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $147.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $86.00M 10-Q · filed 2026-05-07 | $147.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $143.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $61.00M 10-Q · filed 2025-11-07 | $143.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $140.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $82.00M 10-Q · filed 2026-05-07 | $140.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $139.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $58.00M 10-Q · filed 2025-11-07 | $138.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $142.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $80.00M 10-Q · filed 2025-05-07 | $142.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $129.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | $62.00M 10-Q · filed 2024-11-12 | $129.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $97.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $67.00M 10-Q · filed 2024-05-08 | $97.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $103.00M 10-K · filed 2025-02-28 |
| 2022-09-30 | $30.00M 10-Q · filed 2023-11-07 | $103.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $108.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | $73.00M 10-Q · filed 2023-05-03 | $108.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $111.00M 10-K · filed 2024-02-23 |
| 2021-09-30 | $35.00M 10-Q · filed 2022-11-02 | $111.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $110.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $76.00M 10-Q · filed 2022-05-04 | $110.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $100.00M 10-K · filed 2023-02-22 |
| 2020-09-30 | $34.00M 10-Q · filed 2021-11-03 | $100.00M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $93.00M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $66.00M 10-Q · filed 2021-05-06 | $93.00M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $90.00M 10-K · filed 2022-02-23 |
| 2019-09-30 | $27.00M 10-Q · filed 2020-11-04 | $90.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $106.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $63.00M 10-Q · filed 2020-05-06 | $106.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $91.00M 10-K · filed 2021-02-25 |
| 2018-09-30 | $43.00M 10-Q · filed 2019-11-05 | $91.00M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $84.00M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $48.00M 10-Q · filed 2019-05-08 | $84.00M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $83.00M 10-K · filed 2020-02-25 |
| 2017-09-30 | $36.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $83.00M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $83.00M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $47.00M 10-Q · filed 2017-05-10 | $83.00M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $84.00M 10-K · filed 2019-02-26 |
| 2016-09-30 | $36.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $84.00M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $82.00M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $48.00M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $86.00M 10-K · filed 2018-02-27 |
| 2015-09-30 | $34.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | |
| 2014-12-31 | $72.00M 10-K · filed 2017-02-27 | |
| 2013-12-31 | $55.00M 10-K · filed 2016-02-24 | |
| 2012-12-31 | $31.00M 10-K · filed 2015-02-25 | |
| 2011-12-31 | $35.01M 10-K · filed 2014-02-25 | |
| 2010-12-31 | $32.31M 10-K · filed 2013-02-27 | |
| 2009-12-31 | $34.87M 10-K · filed 2012-02-23 | |
| 2008-12-31 | $30.39M 10-K · filed 2011-02-28 | |
| 2007-12-31 | $23.65M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |